Informational Only · Not Legal Advice · Not a Law Firm · Editorial Policy

Gabapentin Lawsuit Filings Rise Over Dementia Injury Claims

Gabapentin lawsuit filings are rising because Philadelphia's Court of Common Pleas created a dedicated mass tort program in fall 2026 for dementia claims against Pfizer and its subsidiaries. According to The Legal Intelligencer, it is the first coordinated docket anywhere in the United States for gabapentinoid cognitive-injury claims. Gabapentinoids are a drug class that includes gabapentin (sold as Neurontin) and pregabalin (Lyrica), originally approved to control seizures and nerve pain. The claims now gathering in Philadelphia say long-term use caused dementia or mild cognitive impairment, and that the manufacturers never warned anyone it could.

Table of Contents

What the Philadelphia mass tort program actually is

A mass tort program is an administrative tool, not a verdict. The court groups similar cases before one judge so discovery, expert challenges and scheduling happen once instead of dozens of times. Philadelphia's Complex Litigation Center has run programs like this for decades, and gabapentinoid dementia claims are its newest. The docket is small so far.

Advertisement

The Lawsuit Information Center reported 28 gabapentin and pregabalin cases in the coordinated litigation as of October 13, 2026, following a case management order entered October 8, 2026. Mass tort programs typically start at that scale; whether this one grows depends on how the early science rulings go. Being consolidated does not mean the cases have been tested. No court has yet ruled on whether the plaintiffs' causation experts can testify, which is usually the decisive moment in a pharmaceutical mass tort.

Why the claims point at dementia

The scientific trigger is a single large study. As Pharmacy Times reported, researchers publishing online July 10, 2025 in BMJ's *Regional Anesthesia & Pain Medicine* matched two groups of 26,414 adults with chronic low back pain treated between 2004 and 2024. Patients with six or more gabapentin prescriptions showed a risk ratio of 1.29 for dementia and 1.85 for mild cognitive impairment.

The finding that drew attention was the age pattern. HealthDay's report notes the effect was strongest in non-elderly adults aged 18 to 64, who had more than twice the dementia and MCI risk of unexposed patients, with risk climbing as prescription counts rose. Mild cognitive impairment sits between normal aging and dementia: memory and thinking problems that are measurable but do not yet prevent independent living. A share of MCI cases progress to dementia, which is why plaintiff firms treat both diagnoses as qualifying injuries.

The failure-to-warn theory

The complaints do not argue that gabapentin should be banned. They argue the label is incomplete. Gabapentin's prescribing information carries central nervous system warnings for somnolence, dizziness and CNS depression, but as MDLinx notes in its clinical review, it does not list dementia or long-term cognitive decline. That gap is the factual spine of every filing.

The named defendants are the companies in the drug's corporate chain: Pfizer Inc., Greenstone LLC, Pharmacia & Upjohn, Pharmacia LLC and Viatris Inc. The Lawsuit Information Center reports the complaints allege each knew or should have known of the neurological risk and failed to warn patients and prescribers. One filed case shows the shape of an individual claim. Crystal Seifers, a Pennsylvania woman, sued Pfizer, Viatris and related entities in the Philadelphia Court of Common Pleas in May 2026, alleging long-term gabapentinoid use caused her early-onset dementia; AboutLawsuits reports she seeks damages above $50,000 plus punitive damages.

Where the evidence is weak

The study behind these cases is observational, and its authors say directly that it cannot establish causation. UPI's coverage sets out the specific gaps: the analysis did not account for gabapentin dose or treatment duration, and reverse causation is plausible — early cognitive symptoms may have prompted the gabapentin prescribing rather than the other way round. The broader literature is softer than the headline number.

📨 Get Free Mass Tort Guides Alerts

Free · No spam · Unsubscribe anytime

A 2026 meta-analysis found only modestly higher odds of dementia, an odds ratio of 1.28 with a 95% confidence interval of 1.10 to 1.50, and that association attenuated when the analysis was limited to studies at low risk of bias. An odds ratio near 1.0 means no detectable difference; 1.28 is a real but small signal, and one that shrinks under stricter methods. Defense experts will press exactly these points at the expert-admissibility stage. A plaintiff considering a claim should understand that the causation science is contested, not settled.

Who plaintiff firms are screening for

There is no federal multidistrict litigation for these claims. The JPML's pending-MDL reports through November 2, 2026 list none, so every claim proceeds individually or through the Philadelphia state program.

That matters practically: there is no national deadline or central registry to join. Firms are applying their own intake criteria, which Sokolove Law describes as roughly: These are screening filters set by law firms, not a legal eligibility standard, and meeting them does not mean a case is viable. "Off-label" means prescribed for a condition the FDA did not approve the drug to treat — legal for doctors to do, and common with gabapentin.

  • Six or more gabapentin prescriptions
  • Use for an off-label condition, most often chronic back pain
  • A dementia or mild cognitive impairment diagnosis
  • Diagnosis frequently before age 65

Practical steps if you think you may be affected

Do not stop taking gabapentin because of a lawsuit. Abruptly discontinuing a gabapentinoid can cause withdrawal and, in people taking it for seizures, can be dangerous.

Any change belongs to the prescribing physician. If you are weighing a claim, the useful work is documentary: Set expectations accordingly: no gabapentin dementia settlement or verdict has been reported, and a program that opened its case management order in October 2026 is years from resolution.

  • Request a full pharmacy dispensing history showing prescription dates and counts
  • Obtain the neurology or primary care records containing the dementia or MCI diagnosis and its date
  • Note what condition the gabapentin was prescribed for
  • Check your state's statute of limitations for personal injury, which can run from the date you discovered the connection

Frequently Asked Questions

Is there a gabapentin class action I can join?

No. These are individual personal injury claims coordinated in a Philadelphia mass tort program, not a class action, and there is no federal MDL. Each plaintiff keeps a separate case with its own medical proof.

Does the lawsuit apply to pregabalin (Lyrica) too?

Yes. The Philadelphia program consolidates gabapentinoid claims covering both gabapentin and pregabalin, and 28 cases across both drugs were reported as of October 13, 2026.

Has the FDA added a dementia warning to gabapentin?

No. The label's CNS warnings cover somnolence, dizziness and CNS depression only. The absence of a dementia warning is what the failure-to-warn claims are built on.


You Might Also Like

Owed money from a settlement? Check what is open at OpenClassActions.com. Caring for someone with dementia? Find practical guides at HelpDementia.com. Working out a skin routine? Evidence-based answers at AcneAdvocate.com. Forgot the name of a movie? Identify it at FindThisMovie.com. Was your data exposed? Track active breaches at DataBreachRadar.com.

We use cookies to run this site, measure how it’s used, and show ads. Choose “Essentials only” to limit cookies to what the site needs to work. Privacy Policy.